Compare FBIZ & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBIZ | VALN |
|---|---|---|
| Founded | 1909 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.7M | 495.5M |
| IPO Year | 2012 | 2021 |
| Metric | FBIZ | VALN |
|---|---|---|
| Price | $63.80 | $5.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $66.00 | $15.50 |
| AVG Volume (30 Days) | ★ 48.1K | 18.0K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.41% | N/A |
| EPS Growth | ★ 14.23 | N/A |
| EPS | ★ 1.44 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.69 | N/A |
| Revenue Next Year | $8.47 | $93.87 |
| P/E Ratio | $44.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $45.90 | $5.04 |
| 52 Week High | $65.49 | $12.25 |
| Indicator | FBIZ | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 59.23 | 46.12 |
| Support Level | $53.68 | $5.10 |
| Resistance Level | $65.49 | $5.52 |
| Average True Range (ATR) | 1.44 | 0.20 |
| MACD | -0.14 | 0.02 |
| Stochastic Oscillator | 55.50 | 44.00 |
First Business Financial Services Inc operates as a bank holding company. The Bank operates as a business bank, delivering a full line of commercial banking products, including commercial loans and commercial real estate loans, to meet the specific needs of small and medium-sized businesses, business owners, executives, professionals, and high-net-worth individuals. The company's products and services include commercial lending, SBA lending and servicing, asset-based lending, equipment financing, factoring, trust, and investment services, treasury management services, and a broad range of deposit products. Geographically, all the business activity functioned through the region of the United States.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.